Company intelligence / Profile preview

Reneo Pharmaceuticals

Irvine, California, United Statesonkuretherapeutics.com ↗

Ownership: Public · RPHM
Development stage: Phase 1

Overview

Reneo’s lead asset mavodelpar failed to meet endpoints in a pivotal Phase III trial for PMM and all development was halted. The company laid off ~70% of staff and suspended its pipeline. A merger with OnKure will shift the company’s focus to precision oncology assets in early clinical development.

Therapeutic areas: OncologyRare DiseasesMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

OKI-219

Phase 1

Indications: Breast cancer, Solid tumors

Partnerships

Novo Holdings/Novo Ventures

Beyond the preview

Go deeper on Reneo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reneo Pharmaceuticals.

Explore the full profile